Follow on Study From RE-ALIGN
- Conditions
- Heart Valve ProsthesisThromboembolism
- Interventions
- First Posted Date
- 2012-01-09
- Last Posted Date
- 2014-07-11
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 158
- Registration Number
- NCT01505881
- Locations
- 🇨🇦
1160.138.11009 Boehringer Ingelheim Investigational Site, Hamilton, Ontario, Canada
🇨🇦1160.138.11001 Boehringer Ingelheim Investigational Site, Saint John, New Brunswick, Canada
🇨🇦1160.138.11012 Boehringer Ingelheim Investigational Site, Newmarket, Ontario, Canada
Pharmacokinetics and Safety Study of BI 695501 in Healthy Subjects
- First Posted Date
- 2012-01-06
- Last Posted Date
- 2019-02-20
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 193
- Registration Number
- NCT01505491
- Locations
- 🇳🇿
1297.1.002 Boehringer Ingelheim Investigational Site, Auckland, New Zealand
🇳🇿1297.1.001 Boehringer Ingelheim Investigational Site, Christchurch, New Zealand
Assessment of Exposure of BI 409306 in Cerebrospinal Fluid (CSF) Relative to Plasma as Well as to Evaluation of the Effect of Different Doses of BI 409306 on the cGMP (Cyclic Guanosine Monophosphate) Levels in CSF in Healthy Male Volunteers
- First Posted Date
- 2011-12-16
- Last Posted Date
- 2024-03-21
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 20
- Registration Number
- NCT01493570
- Locations
- 🇧🇪
1289.3.1 Boehringer Ingelheim Investigational Site, Antwerpen, Belgium
A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation
- Conditions
- Atrial Fibrillation
- Interventions
- First Posted Date
- 2011-12-16
- Last Posted Date
- 2015-10-05
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 1067
- Registration Number
- NCT01493557
- Locations
- 🇺🇸
1160.128.1011 Boehringer Ingelheim Investigational Site, Kalispell, Montana, United States
🇺🇸1160.128.1041 Boehringer Ingelheim Investigational Site, Columbia, Maryland, United States
🇺🇸1160.128.1068 Boehringer Ingelheim Investigational Site, Roswell, Georgia, United States
Post-Marketing Surveillance of Prazaxa® on the Long-term Use in Patients With Nonvalvular Atrial Fibrillation
- Conditions
- Atrial Fibrillation
- Interventions
- Drug: Prazaxa
- First Posted Date
- 2011-12-13
- Last Posted Date
- 2018-01-30
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 6772
- Registration Number
- NCT01491178
- Locations
- 🇯🇵
Boehringer Ingelheim Investigational Site 287, Adachi,Tokyo, Japan
🇯🇵Boehringer Ingelheim Investigational Site 288, Adachi,Tokyo, Japan
🇯🇵Boehringer Ingelheim Investigational Site 291, Adachi,Tokyo, Japan
Tiotropium (18mcg) in Chronic Obstructive Pulmonary Disease (COPD) Patients With a Respiratory Infection
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Drug: Placebo
- First Posted Date
- 2011-12-01
- Last Posted Date
- 2014-06-09
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 140
- Registration Number
- NCT01483625
- Locations
- 🇺🇸
205.479.01037 Boehringer Ingelheim Investigational Site, St. Louis, Missouri, United States
🇺🇸205.479.01007 Boehringer Ingelheim Investigational Site, Easley, South Carolina, United States
🇺🇸205.479.01002 Boehringer Ingelheim Investigational Site, Pittsburgh, Pennsylvania, United States
Single Rising Dose Study of BI 144807 Powder in Bottle in Healthy Male Volunteers
- First Posted Date
- 2011-11-29
- Last Posted Date
- 2013-11-01
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 74
- Registration Number
- NCT01480648
- Locations
- 🇩🇪
1313.1.1 Boehringer Ingelheim Investigational Site, Biberach, Germany
GLORIA-AF Registry Program - Second and Third Phases
- Conditions
- StrokeAtrial Fibrillation
- First Posted Date
- 2011-11-09
- Last Posted Date
- 2021-03-29
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 37235
- Registration Number
- NCT01468701
- Locations
- 🇺🇸
Saint Joseph's Research Institute, Atlanta, Georgia, United States
🇺🇸Seidman Clinical Trials, Delray Beach, Florida, United States
🇺🇸Universal Clinical Research Associates, Doral, Florida, United States
LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung
- First Posted Date
- 2011-11-08
- Last Posted Date
- 2020-04-07
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 319
- Registration Number
- NCT01466660
- Locations
- 🇫🇷
CTR Leon Berard, Lyon, France
🇬🇧Western General Hospital, Edinburgh, United Kingdom
🇨🇳Cancer Hospital of Chinese Academy of Medical Science, Beijing, China
Study on BI 54903 (Inhaled Corticosteroid) Administered Once Daily or Twice Daily Via Respimat Inhaler in Patients With Asthma Inadequately Controlled on Short Acting Beta-2 Agonist (SABA) Therapy Alone
- Conditions
- Asthma
- Interventions
- First Posted Date
- 2011-10-25
- Last Posted Date
- 2013-10-31
- Lead Sponsor
- Boehringer Ingelheim
- Registration Number
- NCT01458886